BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Dasatinib in Combination With Revlimid (and Dexamethasone)
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mgDrug: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mgDrug: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mgDrug: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mgDrug: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT00560391
- Locations
- 🇫🇷
Local Institution, Vandoeuvre Les Nancy, France
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
Methotrexate-Inadequate Response Study
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2492
- Registration Number
- NCT00559585
- Locations
- 🇺🇸
Rheumatic Disease Clinical Research Center, Llc, Houston, Texas, United States
🇺🇸Accurate Clinical Research, Houston, Texas, United States
🇺🇸Cincinnati Rheumatic Disease Study Group, Cincinnati, Ohio, United States
A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: BMS-650032 or Placebo
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT00559247
- Locations
- 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇺🇸Parexel International Corporation, Baltimore, Maryland, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Belatacept in Liver Transplant Recipients
- Conditions
- Immunosuppression in Solid Organ Transplant
- Interventions
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 260
- Registration Number
- NCT00555321
- Locations
- 🇺🇸
Usc University Hospital, Los Angeles, California, United States
🇺🇸Westchester Medical Center, Valhalla, New York, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT00550017
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇬🇧Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Phase IIIB Subcutaneous Abatacept Monotherapy Study
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 119
- Registration Number
- NCT00547521
- Locations
- 🇺🇸
Columbia Arthritis Center, Columbia, South Carolina, United States
🇺🇸Boulder Medical Center, Boulder, Colorado, United States
🇺🇸Physicians East, Pa, Greenville, North Carolina, United States
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 95
- Registration Number
- NCT00546715
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸University Of Virginia Digestive Health Center Of Excellence, Charlottesville, Virginia, United States
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 31
- Registration Number
- NCT00546780
- Locations
- 🇺🇸
Comprehensive Blood And Cancer Center, Bakersfield, California, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸Moores Ucsd Cancer Center, La Jolla, California, United States
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
- First Posted Date
- 2007-10-18
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT00546247
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
- Conditions
- Cancer
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00534807
- Locations
- 🇺🇸
Local Institution, Detroit, Michigan, United States